Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Carcinoma-associated fibroblast (CAF) as prominent cell type of the tumour microenvironment has complex interaction with both the cancer cells and other non-neoplastic surrounding cells. The CAF-derived regulators and extracellular matrix proteins can support cancer progression by providing a protective microenvironment for the cancer cells via reduction of chemotherapy sensitivity. On the other hand, these proteins may act as powerful prognostic markers as well as potential targets of anticancer therapy. In this review, we summarise the clinical importance of the major CAF-derived signals influencing tumour behaviour and determining the outcome of chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
TGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Recent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892
Sun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., True, L., & Nelson, P. S. (2012) · Nature Medicine · doi:10.1038/nm.2890 · Cited by 793
Cancer associated fibroblasts (CAFs) in tumor microenvironment
Xing, F. (2010) · Frontiers in Bioscience · doi:10.2741/3613 · Cited by 682
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633
Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy
Swartz, M. A., Iida, N., Roberts, E. W., Sangaletti, S., Wong, M. H., Yull, F. E., Coussens, L. M., & DeClerck, Y. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0122 · Cited by 542
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development · doi:10.1101/gad.180331.111 · Cited by 541
Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090353 · Cited by 487
Rajski, M., Zanetti-Dällenbach, R., Vogel, B., Herrmann, R., Rochlitz, C., & Buess, M. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-1 · Cited by 355
TGF-beta in CAF-mediated tumor growth and metastasis
Calon, A., Tauriello, D. V. F., & Batlle, E. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.008 · Cited by 342
Wang, W., Li, Q., Yamada, T., Matsumoto, K., Matsumoto, I., Oda, M., Watanabe, G., Kayano, Y., Nishioka, Y., Sone, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1001 · Cited by 297
Nemunaitis, J., Nemunaitis, M., Senzer, N., Snitz, P., Bedell, C., Kumar, P., Pappen, B., Maples, P. B., Shawler, D., & Fakhrai, H. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.15 · Cited by 147
Cited by
Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts
Ziani, L., Chouaib, S., & Thiery, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00414 · Cited by 381
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Neophytou, C. M., Trougakos, I. P., Erin, N., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13174363 · Cited by 371
Cancer Vaccines, Adjuvants, and Delivery Systems
Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200
Exosomes in colorectal carcinoma formation: ALIX under the magnifying glass
Valcz, G., Galamb, O., Krenács, T., Spisák, S., Kalmár, A., Patai, Á. V., Wichmann, B., Dede, K., Tulassay, Z., & Molnár, B. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.72 · Cited by 42
Self-citationValcz, G., Buzás, E. I., Szállási, Z., Kalmár, A., Krenács, T., Tulassay, Z., Igaz, P., & Molnár, B. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0071-9 · Cited by 27
Self-citation
Metadata
- Authors
- Valcz, G., Sipos, F., Tulassay, Z., Molnar, B., & Yagi, Y.
- Venue
- Journal of Clinical Pathology
- Publisher
- BMJ
- Published
- 2014-08-18
- Volume
- 67
- Issue
- 12
- Pages
- 1026-1031
- ISSN
- 0021-9746 (ISSN-L)
- 1472-4146
- OpenAlex
- W2007786148
- Cited by
- 39
- References
- 18
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.